Studies disagree about whether racial and ethnic groups have lower or higher human
papillomavirus (HPV) vaccination uptake, an important issue given large disparities in some …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

These guidelines for the treatment of persons who have or are at risk for sexually transmitted
infections (STIs) were updated by CDC after consultation with professionals knowledgeable …

Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series. Two doses are now widely recommended in some age groups; there are data …

Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …

Background Human papillomavirus (HPV)–related disease remains a significant source of
morbidity and mortality, and this underscores the need to increase HPV vaccination to …

Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

Condyloma acuminatum (CA) is a sexually transmitted disease (STD) caused by human
papillomavirus (HPV) infection. It is important to study the prevalence and distribution of HPV …

OBJECTIVES: We sought to prioritize interventions for increasing human papillomavirus
(HPV) vaccination coverage based on cost-effectiveness from a US state perspective to …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …